US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Prelude Therapeutics, Inc.
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
October 14, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
August 29, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
May 31, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces Pricing of Public Offering
May 18, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces Launch of Proposed Public Offering
May 17, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
May 08, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
March 15, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
March 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PRLD
